BioSpace News Archive

Solarvest BioEnergy Inc. (TSXV: SVS) (“Solarvest” or the “Company”) wishes to provide an update regarding its corporate activities.

iTolerance, Inc. today announced that the United States Patent and Trademark Office (USPTO) has issued patent no. 11,602,547 entitled “FasL-Engineered Biomaterials with Immunomodulatory Function” covering its regenerative SA-FasL microgel immunomodulatory technology, iTOL-100, for preventing or reducing the risks of rejection of cellular or tissue grafts and/or the treatment of autoimmune disorders such as Type 1 Diabetes.

Adaptiiv Medical Technologies Inc., (Adaptiiv), an FDA cleared medical device software company, will be participating in the 2023 Bloom Burton & Co. Healthcare Investor Conference, which will take place on April 25 and 26 at the Metro Toronto Convention Centre.

OpSens (TSX: OPS) (OTCQX: OPSSF), a medical device cardiology-focused company delivering innovative solutions based on its proprietary optical technology, will be participating in the 2023 Bloom Burton & Co. Healthcare Investor Conference, which will take place on April 25 and 26 at the Metro Toronto Convention Centre.

Rakovina Therapeutics Inc. (the “Company”) (TSXV:RKV) today announced the presentation of new data describing the progress of the Company’s kt-3000 drug development program at the American Association of Cancer Research (AACR) annual meeting in Orlando, Florida.

Avadel Pharmaceuticals plc announced that the Compensation Committee of Avadel’s Board of Directors approved the grant of non-statutory options to thirty two new employees to purchase an aggregate of 236,000 ordinary shares under Avadel’s 2021 Inducement Plan.

QIAGEN announced that Steve Rusckowski, an internationally recognized healthcare industry executive and former Chairman, President and CEO of Quest Diagnostics, has joined the Supervisory Board as a new member and will stand for election at the next Annual General Meeting scheduled for June 22, 2023.

Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced that it will report its financial results for the first quarter of 2023 on Thursday, May 4, 2023, following the close of market.

Indaptus Therapeutics, Inc., a biotechnology company focused on discovering and developing transformative therapeutics for patients, announces that CEO Jeffrey A. Meckler will present a corporate overview at the Planet MicroCap Showcase: VEGAS 2023.

Shanghai Junshi Biosciences Co., Ltd. announced that positive interim event-free survival results from the Neotorch study were presented at the ASCO April Plenary Series.